Trending...
- Sober.Buzz the Sober Token : Ticker $BUZZ
- DuoKey to Unveil Encrypted Financial Intelligence Use Case at GISEC Global 2025
- Meditech International Inc. and Los Angeles Rams Continue Strategic Partnership to Enhance Athlete Performance and Recovery
CHADDS FORD, Pa., Feb. 13, 2025 ~ MOBILion Systems, Inc., a leading company in separation science innovation, has announced its participation in the 21st Annual US HUPO Conference. The conference will take place from February 22-26, 2025 in Philadelphia, PA. MOBILion will be showcasing its latest technology, the Parallel Accumulation with Mobility Aligned Fragmentation (PAMAF) operating mode, through various scientific presentations. This new mode promises to increase the speed and sensitivity of LC-MS analysis for proteomics applications.
According to Melissa Sherman, Ph.D., CEO of MOBILion Systems, "Our PAMAF operating mode allows researchers to make more accurate analytical measurements and achieve deeper proteome characterization. This supports scientific discovery in critical areas of human health research." She further explains that by replacing quadrupole isolation with high-resolution ion mobility separation, PAMAF can generate fragmentation data with 10 times higher signal-to-noise ratio and 5 times faster speeds than conventional systems. With almost 100 percent ion utilization, PAMAF is particularly valuable for sample-limited workflows such as single-cell proteomics applications. MOBILion's participation at US HUPO 2025 reflects their commitment to advancing proteomics research through innovative separation science.
More on The PennZone
During the conference, researchers will give presentations demonstrating how PAMAF's capabilities go beyond traditional LC-MS approaches. They will highlight how it reduces chimeric spectra to improve protein quantification and post-translational modification analysis. Additionally, an educational breakfast seminar will feature Prof. Birgit Schilling from The Buck Institute for Research on Aging presenting her team's research on succinylation levels in a sirtuin-5 knockout mouse model for chronic kidney disease (CKD). Using MOBILion's PAMAF mode, they were able to identify hundreds of differentially regulated succinylation sites that may contribute to phenotypic protection against kidney diseases.
The scientific program at the conference will include an oral presentation by Daniel DeBord, Ph.D., Chief Technology Officer at MOBILion, on Tuesday, February 25. The presentation, titled "Abandoning the Quadrupole for MS Fragmentation Analysis: Towards 1,000 Hz Speeds with 100% Ion Utilization Using High Resolution Ion Mobility Precursor Isolation," will be part of Session #11 - Emerging Opportunities in Proteomics from 1:40 PM to 3:00 PM. MOBILion will also have a presence in the poster sessions on Monday and Tuesday, showcasing their research on PAMAF's performance in proteomics applications.
More on The PennZone
In addition to the scientific presentations, MOBILion is also exhibiting at booth number 18 and inviting attendees to learn more about how PAMAF is shaping the future of proteomics. The company believes that their PAMAF operating mode has the potential to revolutionize proteomics research by providing faster and more sensitive LC-MS analysis.
Overall, MOBILion's participation at US HUPO 2025 highlights their dedication to advancing proteomics research through innovative separation science. With their new PAMAF operating mode, they aim to provide researchers with a powerful tool for accurate and efficient proteome characterization. Attendees of the conference can look forward to learning more about this groundbreaking technology and its potential impact on the field of proteomics.
According to Melissa Sherman, Ph.D., CEO of MOBILion Systems, "Our PAMAF operating mode allows researchers to make more accurate analytical measurements and achieve deeper proteome characterization. This supports scientific discovery in critical areas of human health research." She further explains that by replacing quadrupole isolation with high-resolution ion mobility separation, PAMAF can generate fragmentation data with 10 times higher signal-to-noise ratio and 5 times faster speeds than conventional systems. With almost 100 percent ion utilization, PAMAF is particularly valuable for sample-limited workflows such as single-cell proteomics applications. MOBILion's participation at US HUPO 2025 reflects their commitment to advancing proteomics research through innovative separation science.
More on The PennZone
- ScreenPoints Puts Film Investors in the Credits—and in the Money With New FinTech Platform
- Viatris Announces Positive Top-Line Results from Two Pivotal Phase 3 Studies of Novel Fast-Acting Meloxicam (MR-107A-02) for the Treatment of Moderate-to-Severe Acute Pain
- Pathways to Adulthood Conference May 17 at Melville Marriott Honoring NYS Assembly Member Jodi Giglio, Suffolk County Legislator Nick Caracappa
- Adster Techologies awarded US Patent for breakthrough innovation in reducing latency in Ad Serving
- Robert Fabbio Inducted into the Austin Technology Council Hall of Fame
During the conference, researchers will give presentations demonstrating how PAMAF's capabilities go beyond traditional LC-MS approaches. They will highlight how it reduces chimeric spectra to improve protein quantification and post-translational modification analysis. Additionally, an educational breakfast seminar will feature Prof. Birgit Schilling from The Buck Institute for Research on Aging presenting her team's research on succinylation levels in a sirtuin-5 knockout mouse model for chronic kidney disease (CKD). Using MOBILion's PAMAF mode, they were able to identify hundreds of differentially regulated succinylation sites that may contribute to phenotypic protection against kidney diseases.
The scientific program at the conference will include an oral presentation by Daniel DeBord, Ph.D., Chief Technology Officer at MOBILion, on Tuesday, February 25. The presentation, titled "Abandoning the Quadrupole for MS Fragmentation Analysis: Towards 1,000 Hz Speeds with 100% Ion Utilization Using High Resolution Ion Mobility Precursor Isolation," will be part of Session #11 - Emerging Opportunities in Proteomics from 1:40 PM to 3:00 PM. MOBILion will also have a presence in the poster sessions on Monday and Tuesday, showcasing their research on PAMAF's performance in proteomics applications.
More on The PennZone
- Cybersecurity is Protecting Your Personal Information and Your Portfolio
- L2 Aviation Celebrates Grand Opening of New Facility at Cincinnati/Northern Kentucky International Airport (CVG)
- Managing Summer Staffing Surges with Confidence: Why Name Badges Are a Must for Seasonal Success
- Visa Named Title Sponsor of Ascending Athletes' Business Owners Summits for NFL Entrepreneurs
- The Paris Court of International Arbitration Elects Dr. John J. Maalouf as its New President
In addition to the scientific presentations, MOBILion is also exhibiting at booth number 18 and inviting attendees to learn more about how PAMAF is shaping the future of proteomics. The company believes that their PAMAF operating mode has the potential to revolutionize proteomics research by providing faster and more sensitive LC-MS analysis.
Overall, MOBILion's participation at US HUPO 2025 highlights their dedication to advancing proteomics research through innovative separation science. With their new PAMAF operating mode, they aim to provide researchers with a powerful tool for accurate and efficient proteome characterization. Attendees of the conference can look forward to learning more about this groundbreaking technology and its potential impact on the field of proteomics.
Filed Under: Business
0 Comments
Latest on The PennZone
- Children's Hospital of Philadelphia Researchers Recommend New Standard of Care for Families with Hereditary Neuroblastoma Linked to ALK Mutation
- GormanSquared Announces Provisional Patent
- Hubei Heavy Equipment Makes a Striking Appearance at CIMT and Competes with International Brands
- 20 Patents Issued Worldwide, Cementing Company Leadership. First Ever Cable-Free 12-Lead ECG: HeartBeam, Inc. (Stock Symbol: BEAT)
- NASDAQ Uplisting for Higher Market Exposure and Wide Corporate Benefits to AI Boosted Marketing Company On Track Towards $1 Billion Revenue by 2027
- Congressional Men's Health Caucus Shows Bipartisan Consensus and Focus on Prevention, Mental Health, and Closing the Lifespan Gap
- Chewy Chums™ Launches NeverBite™ on Kickstarter
- DuoKey, Axiomtek and Blue Edge Network Partner to Enhance Smart Cities with Privacy-Preserving Urban Safeguarding and Fleet Management
- Fangzhou Launches Otsuka's Third-Generation Leukemia Drug Ponatinib on its Platform
- Viatris Announces Appointments of Frank D'Amelio and Michael Severino, M.D., to the Company's Board of Directors
- Austin Keen Joins WakeFX RopePal as Official Brand Ambassador
- Bonelli Systems Expands Managed IT Services Nationwide, Leveraging Microsoft Azure Expertise
- $4.3 Million Patent Application Waiver Fee Granted by FDA on New Drug Application Fee for Treatment Addressing Suicidal Depression & PTSD: NRX Pharma
- Whistleblower Claims Dental Patient Deaths Likely Due to Book Ban
- xREnergy up as much as +3,094,634% on first day listed on the XRP Ledger. Ticker : $XRE
- Psychiatry's Legacy of Racism and Coercion Highlighted in Restraint Deaths
- New Book 'Cybersecurity Leadership' Guides SME Leaders to Make Smart, Strategic Security Decisions
- Immorta Bio to Present SenoVax™ Cancer Senolytic Immunotherapy Preclinical Data at American Association of Immunologists Meeting
- "Stop scrolling and start watching" - Beloved film recommendation site Criticker gets a major makeover
- Green Energy Solar Expands with New Offices in Port St. Lucie, West Palm Beach, and Orlando